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In situ staining of embryos with
receptor or ligand fusion protein
probes, initially described in 1994
[1,2], is an increasingly widely used
technique to study the ephrins and
other molecular families [3]. In a
recent letter to Current Biology,
Sobieszczuk and Wilkinson [4]
describe interesting results showing
that overexpression of a ligand can
result in masking of its receptor, as
assessed with fusion protein probes,
emphasizing that the results
obtained with such probes always
have to be interpreted carefully. As
this in situ technique is relatively
new, it may be useful to consider
further its advantages and
limitations in comparison with other
available methods. 
Three other techniques used to
study molecular distributions in
vertebrate embryos are RNA in situ
hybridization [5], immunolocalization
[6], and reporter gene insertion [7]. It
is always important to bear in mind
that, by their nature, none of the
available techniques can necessarily
be assumed to give the biologically
‘accurate’ expression pattern. Each of
them gives a different type of
information, and each has unique
advantages, as well as limitations. 
Briefly, RNA in situ hybridization
is relatively quick and reliable, and
the probes and conditions can be
carefully adjusted for a low risk of
cross-reactivity. However, it provides
no direct information on the pattern
or subcellular distribution of proteins,
the functional species one is usually
interested in. Reporter gene insertion
by homologous knock-in or gene
trapping can show the RNA
expression pattern of the targeted
gene and can be highly sensitive and
specific. It may not necessarily reflect
the natural spatial and dynamic
aspects of RNA or protein expression,
however. Immunolocalization can
show detailed protein distributions
and can be highly specific. On the
other hand, here too, there are well
known limitations. Raising antibodies
is time-consuming, expensive, and
sometimes unsuccessful. Results
must be interpreted with caution, as
the antibody may cross-react with
multiple proteins. Furthermore, the
antibody may bind to, or be affected
by, post-translational modifications
such as carbohydrate epitopes, and
may detect degradation products and
other non-functional species. 
Ligand or receptor probes are
generally made as a fusion protein
with an alkaline phosphatase tag [1,2,8]
or an immunoglobulin Fc tag [9,10].
They can be produced far more
quickly than antibodies. In our
experience, production of fusion
proteins that retain binding activity
has been reliable, though this will
depend on the properties of the
individual receptor or ligand. In situ
detection procedures are quick and
simple, usually taking only a few
hours. The fusion probes can be
used in the same types of procedure
as antibodies, but differ in that they
can detect natural ligand–receptor
interactions. It is therefore important
to recognize that the information
gained is qualitatively different. One
obvious advantage is that one can
find novel binding partners, a feature
that has been used to identify a large
number of new receptors and
ligands. Another unique advantage is
that, in the case of receptors that
bind to multiple ligands (or vice
versa), one can obtain global
evidence on the overall distribution
of ligands for that receptor. To look
at this another way, one can ask a
question about the probe — what
distribution of ligands can this
receptor detect in the embryo? In
addition, the technique is
presumably selective for functional,
available forms of molecules that are
capable of ligand–receptor binding. 
As with the other techniques,
though, one must be cautious in
interpreting the results. It may be
hard to draw conclusions about any
single molecule, since the technique
is liable to simultaneously detect
multiple binding partners. In
addition, formation of pre-existing
endogenous receptor–ligand
complexes may mask binding sites for
the probe. For both of these reasons,
it can be informative to compare the
results with another technique, such
as RNA hybridization.
Sobieszczuk and Wilkinson [4]
show that transgenic overexpression
of ephrin-A5 can reduce the binding
of an ephrin-A5–Fc probe to embryos,
providing direct evidence that
masking can indeed occur in an
embryo. As they point out, it is
reassuring that previous studies of
ephrins and Eph receptors have
generally shown a reasonably good
match of fusion-protein binding,
when compared with RNA
hybridization. Their report is
valuable, though, in emphasizing that
masking is a mechanism to consider,
and indicating that ephrins and their
receptors may be less
compartmentalized, and more
overlapping, than might be concluded
based on binding of receptor and
ligand fusion proteins [4].
Does this mean that masking can
be dismissed as a misleading artifact
of the technique? Not necessarily. To
give one example, recent studies of
retinotectal mapping, by in vitro
assays, in vivo overexpression [11],
and gene knockout analysis (D.
Feldheim and J.G.F., unpublished
observations) indicate that a reduced
availability of Eph receptors due to
ligand co-expression may be a
genuine regulatory mechanism in
normal development. Viewed in this
light, if fusion protein probes are
selective for unmasked sites, this
might actually be seen as a useful
aspect of the technique that could
help in assessing the distribution of
available receptor or ligand.
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So, the question remains, which
of the available techniques for
expression pattern analysis most
accurately reflects biological reality?
The best answer may be ‘all of the
above’. No one technique
necessarily gives the whole picture.
Each can provide qualitatively
different types of information, and
all can help in the quest to
understand biological systems.
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Anion transporters of the sulfate
transporter family are of major
interest, as their malfunction is
implicated in three human diseases:
diastrophic dysplasia/achondro-
genesis type IB (DTD) [1,2],
Pendred’s syndrome (PDS) [3] and
congenital chloride diarrhoea (CLD)
[4]. The CLD gene is also
downregulated in intestinal
adenomas and adenocarcinomas [5].
The products of these genes are
distinct but related anion
transporters that contain 12 trans-
membrane helices followed by a
cytoplasmic domain at the carboxyl
terminus. The DTD gene encodes a
sulfate transporter [6], the PDS gene
a potential iodide-chloride
transporter [7] and the CLD gene a
chloride–NaHCO3– exchanger [8].
Related transporters with the same
domain organization, mainly
involved in sulfate transport, are
present in other eukaryotes and in
many bacteria [9]. 
We describe here an unexpected,
statistically significant similarity
between the carboxy-terminal
cytoplasmic domains of these
transporters and the bacterial
antisigma-factor antagonists (ASA)
typified by Bacillus subtilis SPOIIAA.
In a PSI-BLAST search [10,11]
seeded with the SPOIIAA sequence
from Bacillus stearothermophilus, with
a profile inclusion cut-off of 0.01, the
carboxy-terminal domain of the
human disease-associated
transporters and their eukaryotic and
bacterial homologs were detected
with random expectation (E) values
of 10–3–10–4 within five iterations. In
reciprocal searches initiated with the
CLD transporter carboxy-terminal
domain, bacterial ASAs were
detected with E values of 10–4–10–6
in the third iteration. 
The nuclear magnetic resonance
structure of the ASA SPOIIAA [12]
provides the structural framework for
the emerging domain superfamily. A
multiple alignment of this
superfamily was constructed using
the CLUSTALW program [13] and
adjusted using the PSI-BLAST
results (Figure 1). The alignment of
the carboxy-terminal domains of
anion transporters was used for
secondary structure prediction-based
threading through the Protein
Databank (PDB) database using the
PHD-TOPITS program [14]. The
best hit was the PDB entry for
SPOIIAA (PDB code 1AUZ), with a
Z-score of 3.1, which strongly
suggests a structure similar to that of
SPOIIAA. Thus, ASAs and the
cytoplasmic portions of anion
transporters define a previously
undetected, ancient, conserved
domain that we named STAS after
sulfate transporters and antisigma-
factor antagonists.
By mapping the conserved motifs
apparent from the multiple alignment
(Figure 1) onto the SPOIIAA
structure (Figure 2), the conservation
was traced largely to the four strands
that form the scaffold of the STAS
domain. In addition, the turn between
the two amino-terminal strands and
the long loop between strand 3 and
helix 2  are strongly conserved and
inserts appear not to be tolerated in
these elements (Figures 1,2).  Most of
the variability is in the loop between
helix 1 and strand 3, with α-helical
inserts of considerable size seen in
some of the anion transporters
(Figure 1). A comparison of the
alignment with the tertiary structure
shows that the carboxy-terminal
region of the STAS domain forms a
characteristic α-helical handle-like
structure (Figures 1,2).
The identification of the STAS
domain in the ASAs and the anion
transporters provides functional
clues for the regulation of anion
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